Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

6 recruiting

Enrollment Performance

Analytics

N/A

3(50.0%)

Phase 2

2(33.3%)

Phase 3

1(16.7%)

6Total

N/A(3)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04396808Not ApplicableActive Not Recruiting

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

Role: collaborator

NCT06282588Phase 2Recruiting

Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

Role: collaborator

NCT06990542Phase 2Recruiting

Image-guided, Tumor-focused Radiotherapy Treatment in Intermediate and High-risk Prostate Cancer

Role: collaborator

NCT03769415Not ApplicableRecruiting

Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA

Role: collaborator

NCT07282808Not ApplicableRecruiting

Focal or Radical Therapy: a Lesion-based Molecular Evaluation in Prostate Cancer

Role: collaborator

NCT06332274Phase 3Recruiting

tislelizUMaB in canceR Patients With molEcuLar residuaL Disease

Role: collaborator

NCT06426628Recruiting

Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier

Role: lead

NCT02609269Enrolling By Invitation

Decipher Genomics Resource for Intelligent Discovery

Role: collaborator

All 8 trials loaded